Health Professional Radio - Podcast

Dr. Robert Cohen, MD, FACS, board-certified plastic surgeon based in Beverly Hills discusses how and when to advise patients if breast augmentation surgery is something they should be acting on now or waiting for the pandemic to subside and how to schedule surgeries during the pandemic. Robert Cohen, MD, FACS is an Ivy League trained, board certified plastic surgeon who specializes in aesthetic surgery of the breast and body. Dr. Cohen maintains private practices in both Beverly Hills, California and Scottsdale, Arizona.  Dr. Cohen is an educator and lecturer who frequently teaches his innovative techniques at plastic surgery meetings around the world, with particular emphasis on safety and refinements in breast augmentation, augmentation mastopexy, mommy makeovers, fat grafting and complex revision breast surgery. Recognized by his peers and industry as an expert in his field, Dr. Cohen has published numerous articles on aesthetic surgery in the major plastic surgery journals, and has written multiple b

Kasey Frey, second-year Arcadia University Doctor of Physical Therapy student, discusses the new student-run physical therapy pro bono clinic at Arcadia, which opened on March 18. The goal of the Glenside, Pa. clinic is to help address healthcare disparities by providing free physical therapy services while giving students a hands-on learning opportunity, while faculty provide oversight. It is open to all community members for preventative care or rehabilitation from injuries or long-term conditions without requiring a doctor’s referral. There are now 108 university-based clinics nationwide. Kasey Frey is a second year Arcadia University Doctor of Physical Therapy (DPT) student who has been an integral member of the committee to open the pro bono clinic. She graduated from Arcadia in 2019 with a bachelors degree in Healthcare Administration. During her undergraduate studies, she completed a two-summer internship in the physical therapy administration office a local major healthcare system in her hometown of t

Amanda L. Bury, Vice President, Strategic Alliances at TeraRecon discusses their role as the leading provider of medical imaging visualization, AI development, and interoperability technologies that improve patient care and allow providers to be more flexible and offer the most complete access to solutions. Amanda Bury is Vice President of Strategic Alliances for medical imaging AI company TeraRecon. Through her 20 years in healthcare technology, she has become an expert and advocate for simplifying complex healthcare IT infrastructure. She is a speaker and advocate for health systems pushing for greater control of their fragmented imaging process, and tilting those processes so medical teams and financial officers at health systems can better use them with fewer steps and have fewer budget line items to grasp. #TeraRecon #MedicalImaging

Dr. Martha Rodriguez, founder of MMR Healthcare discusses interoperability and her firsthand experience of using data to improve both practice outcomes and patient experience.  She talks about her use of eClinicalWorks who helps providers improve interoperability and have greater access to data, giving them access to live data, giving them access to Carequality and CommonWell Health Alliance networks, and securely exchanging over 50 million records per month with other practices and hospitals. As a well-established primary care physician in Boynton Beach, Florida, Dr. Martha Rodriguez has sculpted a foundation of medicine that prioritizes coordination of care. As a child, Dr. Rodriguez knew this would be her life’s work. She earned her medical degree from the Universidad Central del Este, Dominican Republic, and completed her residency at Hackensack Medical Center, New Jersey in 1993. She went on to establish her private practice in 1997. Currently, Dr. Rodriguez owns and operates her private practice at

Dr. Stephanie Culler, Ph.D., co-founder and CEO of Persephone Biosciences discusses their VOICES (Vaccine Observation to Include all Communities for Equitable Science) study, a non-interventional, single-site study enrolling people in the U.S. being administered a COVID-19 vaccine. The goal is to identify and determine specific gut microbiota and the metabolic processes that are involved in an optimal immune response. Dr. Culler is a graduate of the prestigious Y Combinator accelerator, a recipient of the BIOCOM catalyst award and has spoken at TEDx San Diego. Prior to establishing Persephone Biosciences, she was a senior scientist at Genomatica, where she developed novel microbial synthetic biology technologies for industrial metabolic engineering and led their syngas to chemicals and bio-based butadiene (major component of tires) from renewable feedstocks programs. Dr. Culler also led the development of cell-free transcription-translation (TX-TL) for industrial metabolic engineering as well as the applicati

Returning guest, Dr. Amy Shapiro, MD, Medical Director and CEO at the Indiana Hemophilia & Thrombosis Center and a member of the National Hemophilia Program Coordinating Center (NHPCC) Steering Committee discusses how they are facing the health challenges faced by the bleeding disorders community as outlined in Healthy People 2030 (HP2030) an initiative that addresses the latest public health priorities.  Despite being rare, bleeding disorders were recently named one of the most pressing public health issues in the U.S., alongside conditions such as cancer, diabetes, and heart disease through HP2030. Amy Shapiro, MD, is Medical Director and CEO of the Indiana Hemophilia and Thrombosis Center in Indianapolis and Adjunct Senior Investigator, Clinical Track at the Blood Research Institute in Milwaukee, WI.  After receiving her medical training at New York University School of Medicine in New York City, Dr. Shapiro completed her pediatric internship, residency, and fellowship in pediatric hematology

Nathan White, Chief Client Officer of RxBenefits discusses how data analytics combined with clinical oversights can reduce costs for employers and improve health outcomes for members leveraging the Pharmacy Benefits Optimizer (PBO) model. He talks about the products and technology developments the company has planned for the coming months, the significant milestones that led to the company's growth, and how its recent recapitalization by Advent International positions them to better address an underserved market in 2021. Nathan White, Chief Client Officer, joined RxBenefits in 2017 with more than 18 years of experience in pharmacy client consulting, account management, and medication compliance and safety with both CVS Health and OptumRx. Nathan’s successful career has been fueled by his passion for helping benefit consultants and clients cut through the complexity inherent in the pharmacy ecosystem so that they can make intelligent decisions around pharmacy benefits and developing tailored solutions that mee

John Rothwell, National Vice President of Business Development at Premier, Inc., a leading healthcare improvement company discusses how technology is the differentiator in healthcare and its impact on the changing purchasing landscape. As National Vice President of Business Development, John Rothwell has executive responsibility for Premier’s supply chain and GPO business growth, which includes leading sales, business development, proposal management, and implementation teams. His teams execute on Premier’s performance improvement solutions across supply chain, purchased services, technology and consultative solutions with a focus on reducing costs, improving patient care and outcomes, and improving quality for providers. Rothwell has over 15 years of experience in business development and supply chain leadership roles spanning healthcare and financial services. Prior to his roles in business development, Rothwell held leadership roles within Premier’s sourcing organization. Rothwell led sourcing and negotiat

Dr. Dalia Moawad, MD, Executive Director & Disease Area Lead for Neurological Rare Diseases at Genentech discusses the three things her team learned during the pandemic from the launching of Evrysdi (risdiplam) the first at-home oral medicine for adults and children two months of age and older with spinal muscular atrophy (SMA). Dalia Moawad, M.D. Executive Director, Head of Neurological Rare Diseases, Medical Affairs. Dalia oversees the neurological rare disease portfolio for Genentech.  At Genentech she has lead a portfolio of 10 established products, including most recently for the Evrysdi and the launch of the first influenza antiviral to come to market in 18 years. Between 2011 and 2014, she held several positions in early development and global clinical research with Bristol Myers Squibb and FivePrime Therapeutics. She spent 3 years at UCSF Gastroenterology Division focused on hepatology research before joining Genentech in 2006 with the anti-CD20 programs in immunology, first in late stage cli

In up to 30% of people with chronic low back pain, the SI joint is the hidden source of the pain. SI joint pain is often misunderstood and misdiagnosed. Only 10% of people with SI joint pain receive the treatment and relief they need to pursue active and healthy lives. LinQ by PainTEQ is the only minimally invasive solution on the market backed by extensive clinical research that can provide immediate pain relief. This is how LinQ works Dr. Ajay Antony is an interventional pain physician who joins The Orthopedic Institute after 4 years as faculty at the University of Florida. He earned his bachelor of science at the University of Florida and earned his medical degree at St. George University School of Medicine. He went on to complete his anesthesiology residency and pain medicine fellowship training at UF. During his residency, he served as Chief Resident, was awarded the Michael E. Mahla Outstanding Resident of the Year Award, Best Resident for Outstanding Dedication and Service to the Department, and Outsta

Mike Shoreman, living with a neurological condition called Ramsay Hunt Syndrome shares his personal story and his motivation to write “Diaries of The Unbalanced Paddleboarder: Crash and RISE: From Victim to Thriving Survivor”. Mike Shoreman, known around the world as The Unbalanced Paddleboarder, has overcome adversity in order to inspire and motivate people to overcome their greatest obstacles standing in their way. In his book, “The Diaries of the Unbalanced Paddleboarder: Crash and RISE, From Victim to Thriving Survivor,” he talks about using our fears and struggles as our greatest weapons and drives his audiences to become the STRONGEST versions of themselves.  Mike is a former Paddle Canada Coach and trainer and is an expert in that industry and is the media expert for the Canadian Safe Boating Council. In November 2018 after years of coaching professionally on the water with his own business, Mike developed a sudden neurological condition called Ramsay Hunt Syndrome (a result of having chicken pox

Carisma Therapeutics, Inc. announced (March 2021) that the first patient has been dosed in the Phase 1 multi-center clinical trial for CT-0508, studying the potential of chimeric antigen receptor macrophages (CAR-Ms) for cancer immunotherapy, specifically in solid tumors.  Dr. Debora Barton, MD, Chief Medical Officer at Carisma is here to talk about this novel approach in gene-based therapy development, as it is the first time CAR--engineered macrophages are being studied in humans. CAR-T cell therapy has revolutionized how cancer is treated and revealed the power of gene-based therapies, and it has met challenges with solid tumors. Carisma’s novel approach to immunotherapy may uncover potential treatment options that aim to address the unmet needs of patients, who are battling hard-to-treat cancers. Debora Barton joined Carisma Therapeutics in November 2019. She brings 18 years of oncology experience, both in academia as a practicing physician and in the biotechnology/pharmaceutical industry. In her rol

Jeff Ruby, Founder and CEO of Newtopia, a habit change provider focused on chronic disease prevention, discusses his perspective on why both telehealth and value-based models are set to gain greater adoption in the U.S. Jeff Ruby is a health innovator and entrepreneur who is passionate about shifting the focus of health care from sick care to keeping healthy people healthy. As CEO of Newtopia, which he founded in 2008, he is driving the development of hyper-personalized and highly engaging disease-prevention solutions that deliver sustainable habit change and health results in a scalable and affordable manner.   Previously, Ruby was co-founder and chief operating officer of Cleveland Clinic Canada, a collaboration between the Cleveland Clinic Foundation and Canyon Ranch, and Canada’s leading destination for preventive health and lifestyle management; co-founder and chief operating officer of Life Screening Centres Inc., a cancer screening and prevention company; and co-founder and head of operations

Licensed marriage and family therapist and certified grief and trauma counselor, Kara Bowman discusses her new book entitled "Heartbreak to Hope: Poems of Support for Grief and Loss".  She talks about how the book can help guide people through their experiences of isolation, sadness, and grief. She advises some other ways to find effective methods for dealing with painful emotions and find the capacity to grow, heal, connect and find meaning.    Kara Bowman is a licensed Marriage and Family Therapist who specializes in grief and trauma. She has a part-time private practice in Scotts Valley, California. Kara traveled a long, winding road to arrive at her current profession. She began with an MBA and a career in finance, opened a large, award-winning child development center, worked in non-profit administration, and homeschooled her three children before becoming an NVC Compassionate Communication Trainer. Just as Kara’s children were leaving home and she was settling into her life, her family wa

Danny Altmann, Chairperson of the Global T cell Expert Consortium (GTEC) and Professor of Immunology at Imperial College London discusses the different methods of diagnosing COVID-19, why antibody testing alone is not enough to diagnose the infection, and T cells and their role in diagnosing COVID.  He talks about the GTEC and what they hope to accomplish. Danny Altmann is Professor of Immunology at Imperial College London, where he heads a lab at the Hammersmith Hospital Campus. Professor Altmann has acted in a range of roles during the pandemic in providing advice to policy-makers, including the House of Commons and House of Lords Science Committees. He has served for the past 20 years as editor across journals including Oxford Open Immunology, Immunology and Vaccine. He is a trustee of the Medical Research Foundation and a board member for the African Research Excellence Fund. He previously headed up strategy on infection, immunity and population health at the Wellcome Trust.Professor Altmann’s resear

Returning guest, Dr. Eric Klein, Chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic discusses new 20-year outcomes from a development study of the Oncotype DX Genomic Prostate Score® (GPS) test that was recently published in JCO Precision Oncology (March 2021).  The study highlights the role of the GPS test, the only genomic test for prostate cancer with 20-year outcomes, in assessing the risk of long-term distant metastases (DM) and prostate cancer-specific mortality (PCSM) for patients with localized prostate cancer. Eric A. Klein, MD, is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic. His clinical interests are cancers of the prostate,  testis, and kidney.  For several years, including the current edition, Dr. Klein is listed in Best Doctors in America. Board-certified in urology, Dr. Klein is a frequent lecturer and visiting professor at numerous national and international univer

Addiction specialist, Dr. Melissa Fritsche, discusses what she has observed firsthand within her private practice pertaining to the pandemic exacerbating symptoms of alcohol-related addiction. She also explains why the doctor-patient connection built through in-person engagement is difficult to achieve using telehealth only methods when working with people on a deeply personal recovery journey. Dr. Melissa Fritsche is board certified in both Addiction Medicine and Family Medicine. She began working in addiction in 2017, after feeling called to respond to the opiate epidemic ravaging our country, and now practices solely in this field. Prior to this, she worked in family medicine, urgent care, wound healing, and reproduction health. The unifying theme of her medical practice has always been to care for those others would not. She graduated from the Medical College of Georgia. After an internship in General Surgery in Atlanta, she completed her Family Medicine Residency in Spartanburg, SC. She is licensed to pr

Dave Ross, VP of Commercial Operations - North America at Seqirus discusses the recent FDA approval of FLUCELVAX® QUADRIVALENT, Seqirus’ cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication in children two years of age and older. Dave joined Seqirus in October 2017 as Vice President of Commercial Operations – North America. Prior to this, Dave held several senior roles at Sanofi Pasteur, including Head of Marketing and Sales for VaxServe, a subsidiary of Sanofi Pasteur, Head of Strategic Programs for the Global Influenza Franchise, and Head of US Marketing for the Influenza Franchise. He joined Sanofi Pasteur in 2004 from BASF Corporation, where he also held a number of leadership roles in Sales, Marketing, and Finance during his 16-year tenure. Dave has a BS in Finance from Seton Hall University and an MBA from Fairleigh Dickinson University. #Seqirus #QIVc #InfluenzaVaccine

Dr. Travis Mickle, PhD, President and CEO of KemPharm, Inc., discusses the FDA approval of their new ADHD drug AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsule) for ages 6 to adult, a once-a-day pill with rapid onset of 30 mins and lasts 13 hrs without the side effects associated with the current standard of care. Dr. Mickle co-founded KemPharm Inc. in 2006 with the discovery of the company’s LAT® (Ligand Activated Therapy) prodrug technology. As President, Chief Executive Officer and Chairman of the Board he oversees KemPharm’s business and scientific strategy and is instrumental in the ongoing development of the company’s pipeline of proprietary prodrugs. Prior to founding KemPharm, Dr. Mickle served as Director of Drug Discovery and CMC at New River Pharmaceuticals where he was the principal inventor of Vyvanse®, a prodrug of amphetamine for the treatment of attention deficit hyperactivity disorder (ADHD). Today, Vyvanse is the branded market share leader in the estimated $17 billion plus AD

Returning guest, Larry Kemp, owner of Kemp and Sons General Services discusses how he's had to restructure his business to stay afloat during COVID-19.  He offers guidance on cleaning and disinfecting businesses, public spaces, workplaces, schools and homes. Larry Kemp, managing owner of Kemp and Sons General Services, knows all about success. He overcame borderline poverty and a challenging learning disability during his early childhood to become an award-winning entrepreneur, business strategist and sought-after speaker. After earning a business degree from The University of Texas at Arlington, Kemp joined IBM Executives, where he climbed the ranks to become an integral member of the company’s financial management team. One of the unit’s top sellers, Kemp was responsible for marketing and offering $1 million dollar finance options to qualified clients. When IBM’s company culture began to devolve, Kemp knew entrepreneurship would be the key to his success. In 1998, this fourth generation entrepreneur to